EPS misses by wide margin. Eton Pharmaceuticals reported GAAP diluted EPS of $0.05 for Q4 2025, falling short of the $0.20 consensus estimate by 75.0%. The company posted adjusted diluted EPS of $0.19, matching the prior quarter’s $0.19 but up sharply from a loss of $0.03 per share a year ago. The gap between GAAP and adjusted results reflects $3.9 million in adjustments, primarily non-cash items that boosted adjusted net income to $5.4 million versus GAAP net income of $1.5 million.
Revenue accelerates past expectations. Q4 revenue of $21.3 million topped the $20.6 million consensus by 3.4%, marking an 82.9% surge from $11.6 million in the year-ago quarter. Revenue held flat sequentially at $21.3 million, suggesting the company has stabilized at a higher run rate following mid-2025 growth. Gross profit reached $13.1 million on cost of revenue of $8.2 million, yielding a 61.5% gross margin. Adjusted EBITDA of $6.2 million reflects improving operating leverage as the specialty pharmaceutical portfolio scales.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post Eton Pharmaceuticals (ETON) Q4 Revenue Surges 82.9% YoY to $21.3M, EPS Climbs 266.7% first appeared on Alphastreet.
